Looks like the handed out more options under the 2003 plan. Some new names like Haines, Fellner and I think Kola. Seems like they are expanding the number of people getting options. Haines works for Abingworth so it appears they are in for keeps. Hope so.
Not sure if you saw the news on SGI-110 yesterday but looks like impressive results from my untrained eye. Any thoughts on your end?
Nice. I think that there will be news and events that could drive this higher by Jan 14. They are supposed to announce what disease indication has been selected for Ph3 at ASH in December. That could be real interesting as well as a new IND filed by YE.
True Short. SU2C is also working with SGI-110. Google SU2C and AACR and SGI-110 and you see the release from them with their work with SGI-110 at the AACR this April. This is what really excites me about SGI-110. As you said, appears they could use SGI-110 as a primer. Part of the reason they have expanded their trials to include Ovarian and Lung cancer. First results in 2014/2015. I expect SGI-110 to be partnered out before that.
Yea they are monster. Think they are trying to double revenues by 2017. Great race going on to replace Vidaza by CELG and Dacogen by Astex for next generation drug to treat MDS and AML.
Doubt it short. Think people may be looking at the decline at Astex and thinking it may be time to get back in. I know I am. Should have picked some off at the $4.50 range.
Do you have any thoughts on CLDX? Monster move this year. Market Cap is now $1.2B. Can't see them being worth 3 times Astex especially in light of astex's pipeline.
Totally makes sense in light of the fact that Celgene has so much "funny" $ after the stock rise this year. Can take Astex out for $10 a share and cost less than $1B dollars. For all that you lockup the MDS and some of the AML market. Don't know of anyone working a drug for AML excepy maybe CYCC which is a Dog@#$ firm.
Couple of other things. Dr. de Bono has done good work on AT 13387 and I have been told is a big fan. On SGI-110, the CEO of Astex believes that they are in front in terms of development of the replacement for their Dacogen and the Celgene Vidaza product. Both of those drugs are off patent. Dacogen came off patent in May and Vidaza in 2011. No generic as this point. Astex has guided 2013 revs down to $55M based on a generic Dacogen. I have not seen it yet. I am amazed someone does not buy Astex for all we talked about. Celgene could corner the market by buying Astex. Market is $1.1B in sales per year.
Owed ASTX for a number of years. Finally got paid for my patience this year. Was lucky enough to get out at $6.60 earlier this year. Sold because I thought the stock and market in general was getting a bit frothy. Can't believe that it has retraced back to $4.50 level. Their SGI-110 drug has the potential to be a monster as a replacement for their current approved drug Dacogen. AT 13387 looks interesting. The company really has put its efforts behind these 2 drugs. Love the rest of its pipeline as they have 5 partnered drugs. Of those like LEE-011. They plan on filing a new IND in q4 of this year. Going to get back in soon as to me, the story has not changed since the day I got out.
Appreciate reading your posts. Any feelings AT13387 which is the HSP 90 inhibitor that Astex Phara(ASTX) has? They will have readouts next year I believe on their 3 Ph 2 trails.
Why do you let Free get to you. I think the rest of this board understands you are a valuable contributor to it. Free/Hate/Bucket is/was on days when he/she is properly medicated. He does some serious DD. Being the the psycho that he is, some things set him off. No rhyme or reason. It's to bad. I think it #$%$ him off that he thinks we don't do as much DD on Astex as he does.
PS Commence countdown to post from Free/Hate/Bucket that you, Bat and I are the same person...liftoff in 5,4,3, 2.........
East, think you are right. Might be dipping my foot back in the pool soon again. To me, still like the story. My concern was the overall market and still is.